Amundi Has $58,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Amundi lowered its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 86.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,133 shares of the company’s stock after selling 7,238 shares during the quarter. Amundi’s holdings in Janux Therapeutics were worth $58,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Avanza Fonder AB acquired a new position in Janux Therapeutics during the fourth quarter valued at approximately $139,000. Chicago Capital LLC acquired a new position in Janux Therapeutics during the fourth quarter valued at approximately $230,000. Legato Capital Management LLC acquired a new position in Janux Therapeutics during the fourth quarter valued at approximately $347,000. Y Intercept Hong Kong Ltd acquired a new position in Janux Therapeutics during the third quarter valued at approximately $317,000. Finally, Virtu Financial LLC grew its holdings in Janux Therapeutics by 48.0% during the third quarter. Virtu Financial LLC now owns 7,463 shares of the company’s stock valued at $339,000 after purchasing an additional 2,419 shares during the period. Institutional investors and hedge funds own 75.39% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $70.00 price objective on shares of Janux Therapeutics in a report on Monday, March 3rd. Wedbush reaffirmed an “outperform” rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research note on Friday, February 28th. Lifesci Capital raised shares of Janux Therapeutics to a “strong-buy” rating in a research note on Friday, December 27th. BTIG Research lifted their price target on shares of Janux Therapeutics from $82.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. Finally, Stifel Nicolaus lifted their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Janux Therapeutics currently has an average rating of “Buy” and an average price target of $92.44.

Insider Transactions at Janux Therapeutics

In related news, insider Andrew Hollman Meyer sold 3,334 shares of the business’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $42.29, for a total transaction of $140,994.86. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $3,473,658.31. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ra Capital Management, L.P. bought 110,206 shares of the stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average price of $31.02 per share, for a total transaction of $3,418,590.12. Following the completion of the acquisition, the director now owns 10,141,287 shares of the company’s stock, valued at $314,582,722.74. The trade was a 1.10 % increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 50,002 shares of company stock valued at $2,684,703 over the last 90 days. 29.40% of the stock is owned by corporate insiders.

Janux Therapeutics Stock Down 1.6 %

Shares of JANX stock opened at $29.94 on Friday. The company’s fifty day simple moving average is $36.89 and its 200-day simple moving average is $46.45. The firm has a market cap of $1.77 billion, a PE ratio of -25.59 and a beta of 3.23. Janux Therapeutics, Inc. has a 12 month low of $28.92 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. On average, equities analysts predict that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.